Agenda

Schedule

Full-day Events with Awesome Speakers

Monday, November 26

10.30-11.00
Meetings International - Brain 2018 Conference Keynote Speaker Gregory O Shanick photo

Gregory O Shanick

President & Medical Director

Title

Safety and efficacy of rTMS in treating depression and cognitive dysfunction following traumatic brain injury: Experience of an outpatient neuro-rehabilitation center

Biography

Gregory O'Shanick, M.D., is a former chairman of the board of directors of the BIAA. In May 2011, he was named Medical Director Emeritus for BIAA, after serving for 14 years as its inaugural National Medical Director. Over the past 30 years, he has treated more than 11,000 patients with brain injuries while serving on the faculties of four medical schools and in private practice. Since 1991, Dr. O'Shanick has been the President and Medical Director of the Center for Neurorehabilitation Services in Richmond, Va. He holds board certification in four medical subspecialties (Brain Injury Medicine, Behavioral Neurology and Neuropsychiatry, Psychosomatic Medicine and General Psychiatry) and has published three books, 12 academic textbook chapters and more than 70 peer-reviewed publications. He has presented at national and international medical conferences and has served as an advisor to numerous federal agencies including the Centers for Disease Control and Prevention, Department of Defense, National Institutes of Health and National Institute on Disability and Rehabilitation Research.

Abstract

Presented is a convenience sample of 26 outpatients (9 male; 17 female) who had been treated in an out-patient neurorehabilitation center for traumatic brain injury  (TBI) and developed co-morbid depression, non-responsive to multiple courses of antidepressant therapy, and subsequently received repetitive transcranial magnetic stimulation (TMS) for their depressive syndromes. Time since TBI to TMS varied from 16 months to 53 years, with severity ranging from mild to severe. Measures of mood (PHQ9) generally were reflective of improvement in depressive symptoms. Concomitant improvement in cognition and pain tolerance were also demonstrated with subjective and objective measures. The use of TMS in individuals following TBI with depression appears to be a safe modality offering affective and cognitive benefits based upon this open trial. Further studies are warranted.

 

11.20-11.50
Meetings International - Brain 2018 Conference Keynote Speaker Angel Molina Leon photo

Angel Molina Leon

Neurophysiologist

Title

Electrophysiological study (EMG) in movement disorders delivery for effective anti- leishmania bioactivity

Biography

Dr. Angel Molina Leon is a clinical Neurophysiologist. He has 14 years of experience in the field of Clinical Neurophysiology. He handle the technical realization and analysis of sensory and motor Drives, as well as the realization of the EMG. 3 DIFFERENT TEAMS. Profile Medelec and Medelec Synergy- Oxford. and Medtronic Keypoint System (EMG). 2001-2012 NIHON 2010-2012 CODEN. He handle the technical realization and analysis of multimodal evoked potentials (somatosensory and Electroretinogram Visual and Auditory trunk). Experience in the analysis and quantification of EEG, children and adults and polysomnography. System Profile and Medelec Synergy- Medelec Oxford. and Medtronic Keypoint System (EMG). XLTEK system. Nihon Kohden. -July 2005 to date, nine years of professional work period as Deputy Medical Service Clinical Neurophysiology, Medical Center, Lady of Charity, private facility, concluded with the Social Security, with the realization over the past 7 years 9 EEG week EMG 45 / week, 5-10 PSGN / week. Potential stem auditory 2-3 / week, and 1-2 visual / week potentials, and clinical assessment 2-3 patients / week Sleep Unit, which is to be a total of approximately 60-65 weekly tests for these last 8 years. About 15,600 tests (EEG EMG-PSGN-PEAT-ENP) seen in these last eight years. His experience today is held to have been diagnosed and confirmed through electromyography and EEG / polysomnography and evoked potentials multimodal a varied neuromuscular disease. From January 2011 to date as part of the Clinical Neurophysiology SERVICE UNIVERSITY HOSPITAL VIRGEN CARTAGENA Rosell. As a doctor attached to the service, with the completion of electroencephalography and electromyography.

Abstract

Electromyography (EMG) is the electrophysiological study of the neuromuscular system. It is a complementary test, and prolongation of the clinical neurological study. Given the broad neuromuscular system and brain, in Spain there is a specific and specific pathway via MIR of Neuromuscular which is called Clinical Neurophysiology which includes EEG, EMG, Multimodal Potentials (PEAT, PEV, PESS) and Intraoperative Monitoring. In addition to sleep pathology, and polysomnography and is taught by physicians via MIR with 4 years of training within this specialty. The EMG is designed in each case according to each protocol, according to the specific pathology, it is not the same to see a syndroem of the carpal tunnel that to see a Polyneuropathy or to study in depth a patient with suspicion of lateral sclerosis amiotrofica ELA, and in function of this each protocol has a different duration. One of the characteristics in my judgment of a good neurophysiologist is meticulousness, patience, the taste for this part of medicine and objectivity, it is very important to be objective . 

11.50-12.20
Meetings International - Brain 2018 Conference Keynote Speaker Ali Hashemian photo

Ali Hashemian

Center Director at Brain Wellness Center

Title

Brain Stimulation for treatment of Depression qEEG Brain map guided

Biography

Ali Hashemian is the co-founder and CEO of Brain Science International and Executive Director of Brain Wellness Centers . Under his supervision,  the Center has provided diagnostic evaluations, qEEG Brain Mapping and  non-medication based interventions including neurofeedback (EEG neurofeedback), Auditory Integration Training, Sensory Integration training and coaching to thousands of  clients over the past two decade. Brain Science International has thoughts EEG and qEEG Certification training programs to clinicians throughout the world. Besides over 30 years of experience in neuromodulation and brain stimulation, Dr Hashemian was the 2nd group of clinicians to be trained at Harvard Medical School in their mini-fellowship program in Trans Cranial Magnetic Stimulation in 2003, 5 years before FDA was to clear the procedure in the United States for treatment of medication resistant depression (2008). He has  completed the Professional Program in  Neuropsychological Assessment from the University of California at Berkeley in addition to several hundred hours of continuing education and training in child and adolescent  psychiatric disorders from Harvard Medical School. He is a Certified Berard  Practitioner, as well as a Certified Solisten (by Tomatis) System provider and an Associate  of the International Association of Registered Certified Tomatis Consultants. He has served as the  President of California Biofeedback Society and a member of board of directors of ISNR  Foundation and Chairman of SABA (Society for Advancement of Brain Analysis). Dr.  Hashemian is a frequent lecture of Auditory Integration Training, qEEG Brain Mapping and  Neurofeedback. He is an active participant in the TMS practice and serves on the Insurance Committee and Legal and Business Committee of the Clinical TMS Scoiety.

Abstract

Depression is a world-wide phenomenon which negatively impacts the quality of  life of the sufferers and their care-givers. The number of cases of depression is estimated to be at 16% of the population in The United States and as low as 3% in japan. While many of these patients are successfully treated with pharmacology, some fail to respond to medication or are unable to tolerate medication. 

In the NIH-sponsored STAR-D study (Sequenced Treatment Alternatives to Relieve Depression) it was found that 63.2% of patients suffering from major depression fail to benefit from the first line of antidepressant treatment, and 33% of patients do not respond to any drug treatment.

For these refractory patients, the only alternative, until recently, had been electroconvulsive therapy (ECT).​ In 2008, US Food and Drug Administration cleared repetitive transcranial magnetic stimulation for treatment of medication resistant depression. rTMS is a form of brain stimulation therapy used to treat depression and anxiety. The therapy involves using a magnet to target and stimulate certain areas of the brain believed to be underactive in depressed patients.

Previously, following the manufacturer’s guidelines, all subjects  were treated with either 1 HZ, 10 HZ or 18 HZ.  In our patient population, we undertook the first customized qEEG based TMS treatment to target each patient’s treatment to their resting alpha+1 HZ. 178 patients underwent treatment using Brainsway H1-Coil Deep TMS. Patient ages ranged from 18 to 78 and consisted of 96 females and 82 males. Each patient has a qEEG brain mapping recorded before starting TMS and a couple of weeks after completing of TMS treatment. Treatments were daily (Monday through Friday) consisting of 30 sessions in 6 weeks, followed by a tapering of 3 sessions for week 7, 2 sessions for week 8, and one session for week 9. Each patient completed a Burns Depression Rating Form, a Burns Anxiety Rating Form, and a Phq9 weekly. They also completed a Computerized Cognitive Skill test before starting TMS and at one to two weeks after completing the 36 sessions of TMS. Results indicate that patients achieved an 81% success rate, with success identified as at least 50% reduction in their depression rating forms. This suggests that customization of TMS treatments paired with client qEEG can have a positive impact on the outcomes and that rTMS continues to be a vital tool for treatment of depression.

12.20-12.50
Meetings International - Brain 2018 Conference Keynote Speaker Samuel Ng photo

Samuel Ng

Founder & President Perak Parkinsons Association

Title

Life after Parkinsons

Biography

Samuel Ng on-going personal battle with Parkinson’s since he was 42 (in 2007), which resulted in him having to resign from a 16-year-stint with a top pharmaceutical company, has created in him a deep understanding for people with Parkinson’s

Because of the long duration in the pharmaceutical industry, he fully understand and pick my knowledge in usage & treatment of medication. He had attended numbers of conferences and congress to update my knowledge on Parkinson’s. He went through a clinical trial on a new drugs and working closing with a top professor with Parkinson’s subspecialist neurologist in University Malaya Medical Centre.

He fully understand the struggles of one who suffer from Parkinson’s for he started developing symptoms of the degenerative disorder in 2007, when he was 42 years young.

 

Abstract

Objective:

My objective is to inspiring people with people with Parkinson’s not to be denial stage and hide at home. I’m the founder and President of Perak Parkinson’s Association (PPA). The PPA established 5 years ago. Perak Parkinson’s Association is a non-profitable and non-governmental organization of volunteers and support group committed to people with Parkinson’s (PwP), their family members, friends and caregivers. A group of caring people and professionals (some of whom are PwP themselves) who strive to provide advice, awareness and active networking. 

Research done:

The first subject was a civil engineer with young onset PD for more then 10 years and stay at home for 10 years without come out from the house. He had total lost self-confident, look whitish face and very bad dyskinese. When he was off time, he was completely shut down, could not move, all freeze up and very soft voice that you hardly can heard. A PwP will never listen or accept to others whom do not have the disease because they always said you do not have the symptoms, you do not how I feel.

But I have what they have and some my symptoms they do not have. They no choice but listen to me. I can do it, why not you. It’s matter of your mindset. We need to change into 3P; Positive Thinking, Positive Attitude and Positive Action.

Result:

It took me 3 months for the first time to bring him out from his house to have coffee in nearby coffee shop. He slowly improve by coming more often. After one year, he able to ride bicycle with me and to Perak Parkinson’s Centre.

Conclusion

I believe if you have confident and positive thinking, we can change our life. We need to change our mind set to turn positive. All challenges can be solve, face it and focus to find the solution. Our life is very fragile, just a piece of phlegm can kill you. I still love this wonderful world and wanted enjoy the happiness come every moment. Kindly remember, daily exercise is important for each of us.

 

14.00-14.30
Meetings International - Brain 2018 Conference Keynote Speaker Angel Molina Leon photo

Angel Molina Leon

Neurophysiologist

Title

WORKSHOP on Electromiography and electroneurography and explore it's therapeutics

Biography

Dr. Angel Molina Leon is a clinical Neurophysiologist. He has 14 years of experience in the field of Clinical Neurophysiology. He handle the technical realization and analysis of sensory and motor Drives, as well as the realization of the EMG. 3 DIFFERENT TEAMS. Profile Medelec and Medelec Synergy- Oxford. and Medtronic Keypoint System (EMG). 2001-2012 NIHON 2010-2012 CODEN. He handle the technical realization and analysis of multimodal evoked potentials (somatosensory and Electroretinogram Visual and Auditory trunk). Experience in the analysis and quantification of EEG, children and adults and polysomnography. System Profile and Medelec Synergy- Medelec Oxford. and Medtronic Keypoint System (EMG). XLTEK system. Nihon Kohden. -July 2005 to date, nine years of professional work period as Deputy Medical Service Clinical Neurophysiology, Medical Center, Lady of Charity, private facility, concluded with the Social Security, with the realization over the past 7 years 9 EEG week EMG 45 / week, 5-10 PSGN / week. Potential stem auditory 2-3 / week, and 1-2 visual / week potentials, and clinical assessment 2-3 patients / week Sleep Unit, which is to be a total of approximately 60-65 weekly tests for these last 8 years. About 15,600 tests (EEG EMG-PSGN-PEAT-ENP) seen in these last eight years. His experience today is held to have been diagnosed and confirmed through electromyography and EEG / polysomnography and evoked potentials multimodal a varied neuromuscular disease. From January 2011 to date as part of the Clinical Neurophysiology SERVICE UNIVERSITY HOSPITAL VIRGEN CARTAGENA Rosell. As a doctor attached to the service, with the completion of electroencephalography and electromyography.

Abstract

Electromyography (EMG) is the electrophysiological study of the neuromuscular system. It is a complementary test, and prolongation of the clinical neurological study. Given the broad neuromuscular system and brain, in Spain there is a specific and specific pathway via MIR of Neuromuscular which is called Clinical Neurophysiology which includes EEG, EMG, Multimodal Potentials (PEAT, PEV, PESS) and Intraoperative Monitoring. In addition to sleep pathology, and polysomnography and is taught by physicians via MIR with 4 years of training within this specialty. The EMG is designed in each case according to each protocol, according to the specific pathology, it is not the same to see a syndroem of the carpal tunnel that to see a Polyneuropathy or to study in depth a patient with suspicion of lateral sclerosis amiotrofica ELA, and in function of this each protocol has a different duration. One of the characteristics in my judgment of a good neurophysiologist is meticulousness, patience, the taste for this part of medicine and objectivity, it is very important to be objective

  • Transcranial Magnetic Stimulation (TMS)
    Location: Tokyo
  • Electroconvulsive therapy (ECT)
    Location: Tokyo